Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTUARY extension study of amlitelimab maintenance dosing in moderate-to-severe atopic dermatitis
MOH_2024-07-25_013546Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (11 arms), sponsored by Sanofi. Primary endpoint: Not reported in registry entry. Started Jun 2024; status: recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2024-07-25_013546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-25_013546.